Veraxa Biotech

Executive Summary

Veraxa Biotech is a private German biotechnology company founded in 2020 and headquartered in Munich. The company is dedicated to building a premier discovery and development engine for next-generation antibody-based therapeutics, with a primary focus on oncology. Veraxa leverages proprietary technologies to create novel antibody formats, including bispecific antibody-drug conjugates (ADCs) and T cell engagers, aiming to address significant unmet needs in cancer treatment. While the company remains in an early stage with no disclosed funding or pipeline details, its strategic focus on innovative antibody formats positions it within the highly competitive biotech landscape. Veraxa's success will depend on advancing its proprietary platforms, attracting partnerships, and securing financing to move candidates toward the clinic.

Upcoming Catalysts (preview)

• H2 2026Series A Financing Round60% success
• Q4 2026Preclinical Data Readout for Lead Program40% success
• H1 2027Research Collaboration or Licensing Deal35% success